Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|October 1, 2019
How AI/ML and advanced techniques are enhancing clinical development: Lessons learned from use in study design, patient and site ID, safety, and risk-based monitoring
Author(s)IQVIA
Using AI/ML and advanced techniques in clinical development is more than just hype – it is greatly enhancing clinical trials today! Learn how pharmaceutical firms are realizing the benefits of better study design, faster recruitment, automated safety approaches and more informed, faster decision-making with risk-based and centralized monitoring. Live: Tuesday, Oct. 1, 2019 at 11am EDT On demand available after airing until Oct. 1, 2020. Register free: Register free
Register free:
Event Overview:
Clinical trials create vast amounts of disparate data sets, historically generated and retained in silos. Today, integrating, gaining access to and leveraging the breadth of available data requires advanced technologies and innovative approaches.
Learn how IQVIA is using artificial intelligence (AI) and machine learning (ML) with advanced and predictive analytics to transform clinical development. IQVIA will share examples of AI/ML and analytics in use today, and cite benefits being generated. Use cases and lessons learned include:
- Study design
- Site ID & patient population identification
- Safety automation
- Clinical monitoring/risk-based monitoring
Register today and hear how companies are realizing the benefits of AI/ML and advanced techniques to work in their trials – today!
Key Learning Objectives:
Using AI/ML and advanced techniques in clinical development is more than just hype – it is greatly enhancing clinical trials today!
Learn how pharmaceutical firms are realizing the benefits of AI/ML and advanced techniques in their trials with better study design, faster site and patient identification, enhanced and automated safety approaches and more informed, faster decision-making with risk-based and centralized monitoring.
Speakers: Lucas Glass, Global Head of Analytics Center of Excellence, R&D, IQVIA
Gary Shorter, Head of Artificial Intelligence, IQVIA
Rajneesh Patil, Head of Process Design & Analytics, Centralized Monitoring, Services, IQVIA
Time and date: Tuesday, Oct. 1, 2019 at 11am EDT
On demand available after airing until Oct. 1, 2020.
Sponsor: IQVIA
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5